RedHill Biopharma (RDHL) Share-based Compensation (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Share-based Compensation data on file, last reported at $1.1 million in Q4 2022.

• Share-based Compensation for Q4 2022 came in at $1.1 million, down 39.36% year-over-year; the trailing twelve-month figure through Dec 2022 was $5.7 million (down 44.43% YoY), and the FY2025 annual result was $457000.0, down 31.28% from the prior year.
• Share-based Compensation declined to $1.1 million in Q4 2022 per RDHL's latest filing, from $1.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $5.3 million in Q2 2021 and troughed at $468000.0 in Q3 2018.
• A 5-year average of $1.3 million and a median of $839000.0 in 2018 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2021 and 2022: Share-based Compensation jumped 746.55% in 2021, then sank 88.28% in 2022.
• A 5-year view of Share-based Compensation shows it stood at $671000.0 in 2018, then gained by 11.62% to $749000.0 in 2019, then jumped by 44.46% to $1.1 million in 2020, then soared by 73.29% to $1.9 million in 2021, then tumbled by 39.36% to $1.1 million in 2022.
• Business Quant data shows RDHL's Share-based Compensation at $1.1 million in Q4 2022, $1.6 million in Q3 2022, and $618000.0 in Q2 2022.